



	Q2 19/20	Q2 20/21	YTD 19/20	YTD 20/21		Q2 19/20	Q2 20/21	YTD 19/20	YTD 20/21
Income statement, continuing operations (EUR m)					Growth drivers, continuing operations (%)				
Revenue	239.6	260.0	459.6	503.5	Organic growth	6%	10%	4%	10%
Gross profit	141.6	147.3	274.1	283.3	Volume/mix	na	5%	na	5%
EBITDA b.s.i.	93.8	93.1	173.9	180.9	Price	na	5%	na	5%
EBIT b.s.i.	77.1	70.1	140.9	131.5	Currencies	-1%	-10%	-1%	-9%
EBIT	75.7	65.9	138.7	120.9	M&A	-	9%	-	9%
Net financial items	(5.2)	(4.4)	(7.8)	(11.0)	EUR growth	5%	9%	3%	10%
Profit for the period	58.9	53.0	108.8	94.4	Organic growth by region, continuing operations (%)				
Cash flow and investments, continuing operations (EUR m)					EMEA	2%	4%	-1%	6%
Operating cash flow	61.4	58.2	91.3	97.0	NA	7%	7%	8%	8%
Investing cash flow	(26.3)	(25.7)	(55.0)	(401.9)	LATAM	18%	32%	14%	36%
Free cash flow b.s.i.a.d.	41.6	41.8	49.1	34.9	APAC	4%	10%	1%	3%
M&A	-	-	-	(319.0)	Food Cultures & Enzymes (EUR m / %)				
Balance sheet, Group (EUR m)					Revenue	172.5	168.7	338.6	334.0
Total assets			2,109.8	3,236.0	Organic growth	5%	8%	4%	8%
Invested capital			1,844.2	2,933.4	Volume/mix	4%	2%	3%	2%
Net working capital			265.0	282.1	Currencies	-1%	-10%	0%	-9%
Equity			782.2	980.0	M&A	-	-	-	-
Net interest-bearing debt			879.2	1,680.8	EUR growth	4%	-2%	4%	-1%
Key ratios (%)					EBITDA	67.1	64.6	131.6	129.8
Continuing operations					EBITDA margin	38.9%	38.3%	38.9%	38.9%
Gross margin	59.1%	56.7%	59.6%	56.3%	EBIT	55.6	52.2	108.8	103.0
EBITDA margin b.s.i.	39.1%	35.8%	37.8%	35.9%	EBIT margin	32.2%	31.0%	32.1%	30.8%
EBIT margin b.s.i.	32.2%	27.0%	30.7%	26.1%	ROIC excl. goodwill			37.1%	32.9%
Underlying EBIT b.s.i. margin ¹	na	30.9%	na	29.8%	Health & Nutrition (EUR m / %)				
R&D	8.4%	8.5%	8.8%	8.6%	Revenue	67.1	91.3	121.0	169.5
Capex	8.8%	7.9%	9.7%	14.9%	Organic growth	8%	14%	2%	14%
Group					Volume/mix	9%	13%	3%	13%
ROIC excl. goodwill	31.8%	21.9%	30.2%	22.3%	Currencies	-1%	-9%	0%	-9%
ROIC	18.4%	10.8%	17.3%	11.0%	M&A	-	31%	-	35%
Net debt to EBITDA b.s.i.			1.9x	3.7x	EUR growth	7%	36%	2%	40%
					EBITDA	26.7	28.5	42.3	51.1
					EBITDA margin	39.8%	31.2%	35.0%	30.1%
					EBIT	21.5	17.9	32.1	28.5
					EBIT margin, %	32.1%	19.6%	26.5%	16.8%
					Underlying EBIT margin ¹	na	30.9%	na	26.9%
					ROIC excl. goodwill			21.5%	10.1%

Revenue split by business, YTD



Revenue split by region, YTD



¹See Q2 2020/21 company announcement, p. 20, for reconciliation of underlying margins.